We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Akero Therapeutics announced the dosing of the first patient in its Phase 2a clinical study of AKR-001, a novel FGF21 analog, for the treatment of NASH (the BALANCED study).
The first group of subjects have been dosed in a single-dose three-way crossover pharmacokinetic (PK) study with RHB-105 versus the active comparators in the confirmatory Phase III study and in a food-effect study with RHB-105 in healthy volunteers